Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.93 |
| ▸ | TSHR | P16473 | 2/20 | 0.69 |
| ▸ | SAT1 | P21673 | 3/20 | 0.65 |
| ▸ | KDM1A | O60341 | 5/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 3/20 | 0.47 |
| ▸ | CA6 | P23280 | 3/20 | 0.47 |
| ▸ | CA7 | P43166 | 3/20 | 0.47 |
| ▸ | CA9 | Q16790 | 3/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.47 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA4 | P22748 | 2/20 | 0.47 |
| ▸ | CA5A | P35218 | 2/20 | 0.47 |
| ▸ | CA3 | P07451 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5932612 | 1.00 | CYP2C19 (1.00) | CYP2C19MEN1KMT2AGLACYP1A2 | |
| SCHEMBL9241890 | 1.00 | CYP2C19 (1.00) | CYP2C19MEN1KMT2AGLACYP1A2 | |
| Bis(Ethyl)Norspermine SCHEMBL5548459 | 0.96 | CYP2C19 (0.93) | CYP2C19MEN1KMT2AGLACYP1A2 | |
| SCHEMBL4171429 | 0.96 | CYP2C19 (1.00) | CYP2C19MEN1KMT2AGLACYP1A2 | |
| SCHEMBL7871599 | 0.96 | CYP2C19 (1.00) | CYP2C19MEN1KMT2AGLACYP1A2 | |
| SCHEMBL4167237 | 0.96 | CYP2C19 (1.00) | CYP2C19MEN1KMT2AGLACYP1A2 | |
| SCHEMBL6899291 | 0.96 | CYP2C19 (1.00) | CYP2C19MEN1KMT2AGLACYP1A2 | |
| SCHEMBL12085576 | 0.96 | CYP2C19 (0.93) | CYP2C19MEN1KMT2AGLACYP1A2 | |
| SCHEMBL4157457 | 0.96 | CYP2C19 (1.00) | CYP2C19MEN1KMT2AGLACYP1A2 | |
| Bis(Ethyl)Spermine SCHEMBL7092466 | 0.96 | CYP2C19 (1.00) | CYP2C19MEN1KMT2AGLACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 414 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026044253-A1 | GENETICALLY ENCODED FLUORESCENT SENSORS FOR VISUALIZING POLYAMINE LEVELS, UPTAKE, AND DISTRIBUTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-02-26 | — | — | WO | claimed |
| US-20250332118-A1 | NOVEL ORAL CARE FORMULATIONS FOR TREATMENT OF XEROSTOMIA | LIVIONEX INC (US) | 2025-10-30 | — | — | US | claimed |
| EP-4504163-A1 | NOVEL ORAL CARE FORMULATIONS FOR TREATMENT OF XEROSTOMIA | Livionex, Inc. (US) | 2025-02-12 | — | — | EP | claimed |
| CN-119384274-A | Novel oral care formulations for the treatment of xerostomia | 利维昂尼克斯公司 | 2025-01-28 | — | — | CN | claimed |
| US-12194010-B2 | Methods and compositions to prevent and treat disorders associated with mutations in the ODC1 gene | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2025-01-14 | — | — | US | claimed |
| WO-2023196667-A1 | NOVEL ORAL CARE FORMULATIONS FOR TREATMENT OF XEROSTOMIA | LIVIONEX, Inc. (US) | 2023-10-12 | — | — | WO | claimed |
| WO-2023147169-A2 | NOVEL LIQUID FORMULATIONS FOR IRON CHELATION | LIVIONEX, Inc. (US) | 2023-08-03 | — | — | WO | claimed |
| EP-2941128-B1 | ANTIMICROBIAL COMPOSITIONS | BHUSHAN RAJIV (US) | 2023-06-28 | — | — | EP | claimed |
| CN-115310212-B | Method for sampling characteristic data of automobile shock absorber | 中汽研（天津）汽车工程研究院有限公司 | 2023-03-24 | — | — | CN | claimed |
| US-20220362381-A1 | REMOTELY TRIGGERED THERAPY | BAMBU VAULT LLC (US) | 2022-11-17 | — | — | US | claimed |
| US-20070078187-A1 | METHODS FOR TREATING VIRAL INFECTIONS USING POLYAMINE ANALOGS | PATHOLOGICA, LLC. (US) | 2007-04-05 | — | — | US | claimed |
| WO-2007035957-A2 | METHODS FOR TREATING VIRAL INFECTIONS USING POLYAMINE ANALOGS | PATHOLOGICA, LLC. (US) | 2007-03-29 | — | — | WO | claimed |
| US-7087648-B1 | Methods for modulating macrophage proliferation using polyamine analogs | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-08-08 | — | — | US | claimed |
| US-20050159493-A1 | Methods for modulating macrophage proliferation using polyamine analogs | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2005-07-21 | — | — | US | claimed |
| EP-1448183-A2 | TREATMENT OF NEURODEGENERATIVE DISORDERS THROUGH THE MODULATION OF THE POLYAMINE PATHWAY | ALS Therapy Development Foundation, Inc. (US) | 2004-08-25 | — | — | EP | claimed |
| US-20030158262-A1 | Treatment of neurodegenerative disorders through the modulation of the polyamine pathway | ALS THERAPY DEVELOPMENT FOUNDATION, INC. | 2003-08-21 | — | — | US | claimed |
| WO-2003043616-A2 | TREATMENT OF NEURODEGENERATIVE DISORDERS THROUGH THE MODULATION OF THE POLYAMINE PATHWAY | ALS THERAPY DEVELOPMENT FOUNDATION, INC. (US) | 2003-05-30 | — | — | WO | claimed |
| JP-2001520990-A | — | — | 2001-11-06 | — | — | JP | claimed |
| EP-1027040-A2 | METHODS FOR MODULATING MACROPHAGE PROLIFERATION USING POLYAMINE ANALOGS | The Regents of the University of California (US) | 2000-08-16 | — | — | EP | claimed |
| WO-1999021542-A2 | METHODS FOR MODULATING MACROPHAGE PROLIFERATION USING POLYAMINE ANALOGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-05-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250332118-A1 | NOVEL ORAL CARE FORMULATIONS FOR TREATMENT OF XEROSTOMIA | STOM, TAS2R40, SLC14A1 | CYP2C19 2846/4885MEN1 3203/4885KMT2A 2988/4885 |
| US-20220362381-A1 | REMOTELY TRIGGERED THERAPY | CD47, HSP90AA1, HSF1 | CYP2C19 2818/4885MEN1 182/4885KMT2A 1632/4885 |
| US-20070078187-A1 | METHODS FOR TREATING VIRAL INFECTIONS USING POLYAMINE ANALOGS | GLS, SHMT2, ARG2 | CYP2C19 3039/4885MEN1 446/4885KMT2A 1328/4885 |
| US-20030158262-A1 | Treatment of neurodegenerative disorders through the modulation of the polyamine pathway | ODC1, SRM, OTC | CYP2C19 4855/4885MEN1 4302/4885KMT2A 1837/4885 |
| US-20050159493-A1 | Methods for modulating macrophage proliferation using polyamine analogs | ARG1, MKI67, CSF1R | CYP2C19 4826/4885MEN1 865/4885KMT2A 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.